首頁 › 多發性骨髓瘤 › 佛羅里達 › Jacksonville
Jacksonville, FL 的 多發性骨髓瘤 臨床試驗
18 項針對 多發性骨髓瘤 的研究正在 Jacksonville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
招募中
- Mayo Clinic in Florida, Jacksonville
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
招募中2 期
- Mayo Clinic in Florida, Jacksonville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Mayo Clinic Jacksonville, Jacksonville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Mayo Clinic Jacksonville, Jacksonville
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
招募中1 期
- Cancer Specialists of North Florida, Jacksonville
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic in Florida, Jacksonville
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- Mayo Clinic - Jacksonville, Jacksonville
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- Baptist MD Anderson Cancer Center, Jacksonville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- Mayo Clinic in Florida, Jacksonville
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Florida, Jacksonville
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Hospital - Florida, Jacksonville
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Jacksonville
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
招募中2 期
- Mayo Clinic - Florida, Jacksonville
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic in Florida, Jacksonville
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
招募中2 期
- Mayo Clinic in Florida, Jacksonville
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
招募中3 期
- Mayo Clinic in Florida, Jacksonville
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
招募中2 期
- Mayo Clinic in Florida, Jacksonville
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
招募中1 期
- Cancer Specialists, LLC, Jacksonville
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA41 項研究
- Houston, TX38 項研究
- Durham, NC37 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- Rochester, MN24 項研究
- St. Louis, MO24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Chicago, IL22 項研究
Jacksonville 的其他研究
- 乳癌40 項研究
- 非小細胞肺癌39 項研究
- 癌症（所有類型）29 項研究
- 轉移性癌症28 項研究
- 大腸直腸癌27 項研究
- 前列腺癌26 項研究
- 肥胖症25 項研究
- 心臟衰竭21 項研究
- 胰臟癌20 項研究
- 過重19 項研究
- 肺癌17 項研究
- 中風16 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。